Table 1 Demographic and clinical characteristics of the patients analyzed
Characteristics | Study group | p | |
|---|---|---|---|
Self-care education (n = 44) | Control (n = 42) | ||
Age (years) | 53.4 ± 9.7 | 52.9 ± 10.4 | 0.61 |
Male gender | 23 (52.27%) | 21 (50%) | 0.52 |
Body weight (kg) | 70.6 ± 11.3 | 71.1 ± 12.4 | 0.86 |
BMI (kg/m2) | 25.9 ± 4.2 | 26.2 ± 4.6 | 0.64 |
Baseline depression score | 24.6 ± 13.3 | 16.1 ± 11.6 | 0.31 |
Baseline depression | 0.45 | ||
No (score ≤ 38) | 33 (75%) | 34 (80.95%) | |
Yes (score ≥ 38) | 11 (25%) | 8 (19.05%) | |
Smoking year before diagnosis | 13 (29.55%) | 8 (19.05%) | 0.21 |
Still smoking at baseline | 4 (9.09%) | 5 (11.9%) | 0.84 |
Tumour site | 0.72 | ||
Rectum | 10 (22.73%) | 12 (28.57%) | |
Colon | 25 (56.82%) | 21 (50%) | |
Gastric | 9 (20.45%) | 9 (21.43%) | |
Tumour Stage TNM | 0.61 | ||
II | 7 (15.91%) | 9 (21.43%) | |
III | 23 (52.27%) | 20 (47.62%) | |
IV | 14 (31.82%) | 13 (30.95%) | |
Previous tumour resection | 35 (79.55%) | 32 (76.19%) | 0.48 |
Time between tumour resection and inclusion in chemotherapy (days) | 61.5 ± 11.4 | 63.2 ± 13.1 | 0.73 |
Concomitant radiotherapy | 3 (6.82%) | 5 (11.9%) | 0.11 |
Days since first chemotherapy | 23.7 ± 12.6 | 20.4 ± 11.4 | 0.32 |
Chemotherapy protocol | 0.41 | ||
Oxaliplatin + capecitabine | 17 (38.64%) | 19 (45.24%) | |
Fluorouracil + leucovorin | 9 (20.45%) | 8 (19.05%) | |
Oxaliplatin + leucovorin + fluorouracil | 7 (15.91%) | 9 (21.43%) | |
Others | 11 (25%) | 6 (14.28%) | |